Clinigen has acquired SSI Strategy for an undisclosed amount. The acquisition sees Clinigen, a company with a focus on global commercialisation for biotech and pharmaceutical innovators, integrate SSI Strategy's deep expertise in clinical development and operations. SSI Strategy is known for being a strategic partner to biotech companies, providing adaptive support and integrating business acumen with specialized expertise across the drug development lifecycle, from concept to commercialization.
SSI Strategy's core offering involves working as an embedded team within client organizations, scaling specialized skill sets in areas such as Clinical Development & Operations, Regulatory Affairs, Pharmacovigilance, Medical Affairs, Quality, and Program Management. Their mission is to "Build better biotechs" by fostering seamless collaboration, informed decision-making, and accelerated progress throughout the complex journey of bringing a therapeutic to market. They aim to position clients' full-time employees for greater success by complementing existing teams with tailored support.
This strategic acquisition aims to create a more comprehensive service offering for biotech innovators. By incorporating SSI Strategy's capabilities, Clinigen expands its reach upstream into the crucial early development and strategic planning phases. The synergy is expected to provide clients with an integrated path from initial clinical strategy through to global commercialisation, streamlining operations and decision-making for biotech companies navigating product development. The combined entity will offer a continuum of support, addressing critical needs at every stage.
The integration of SSI Strategy's development expertise with Clinigen's commercialisation strengths is anticipated to enhance value for clients seeking end-to-end solutions. This move positions the combined organization to support biotechs more holistically, enabling accelerated progress and improved efficiency from scientific concept to patient access globally.